Is taking Ozempic cheating? On the evidence, no. Cheating means breaking a fair rule for an advantage, and body weight does not follow a fair rule of effort. Twin studies put the heritability of BMI at 47% to 90%, and the trials show the drugs work only while people keep taking them.
The argument of this piece is that the cheating question is a category error with two halves, and both halves are wrong. The first half assumes that weight is a contest of willpower with fair rules, so a drug that changes appetite is an unfair edge. The genetics and physiology data say the contest was never fair. The second half assumes the drug is a shortcut, something taken once that skips the work. The withdrawal trials say the opposite: stop semaglutide and most of the weight returns within a year. What survives the data is a narrower and more honest question, about who the treatment is for, and the public has already drawn that line more clearly than the debate admits.
Nothing below is medical advice, and this page does not tell anyone whether to start, stop or continue any medicine. Doses appear only as the names of trial arms, the way the papers report them. Every figure comes from a source read on 18 November 2026 and linked at the foot of the page. A note on names: Ozempic is approved by the FDA for type 2 diabetes, and the same molecule, semaglutide, is approved for chronic weight management as Wegovy. The STEP trials below tested the Wegovy dose. In everyday speech "Ozempic" covers both, which is why this page uses the word people actually type.
Is taking Ozempic cheating, or is it treatment?
Taking Ozempic or Wegovy is cheating only if body weight is governed by a fair rule that everyone faces equally, and the evidence says it is not. A systematic review by Elks and colleagues in Frontiers in Endocrinology in 2012 pooled 88 estimates from twin studies covering 140,525 twins and found the heritability of BMI ranged from 0.47 to 0.90, with a median of 0.75. Heritability is a population statistic, not a personal destiny, but it means that most of the variation in weight between people in those samples tracked their genes rather than their effort. A contest in which most of the score is set before the start is not one where an aid to the disadvantaged player counts as breaking the rules.
Medicine has also moved the category itself. In January 2025 a Lancet Commission of 58 experts, including people with lived experience of obesity, defined clinical obesity as a chronic, systemic illness caused by excess fat impairing the function of organs and tissues, and separated it from preclinical obesity, where function is preserved. The Commission's criteria have been endorsed by 76 organisations worldwide. Once a condition is defined as an illness, the vocabulary changes: nobody calls insulin cheating at diabetes or statins cheating at cholesterol. The word "cheating" survives in the obesity debate because the older moral frame survives, not because the clinical frame supports it.
Why doesn't willpower alone keep weight off?
Willpower alone rarely keeps weight off because the body responds to weight loss by spending less energy, and that response can persist for years. The clearest human evidence is a 2016 study in the journal Obesity that followed 14 contestants from the television show The Biggest Loser. They lost an average of 58.3 kg during the 30-week competition. Six years later they had regained 41.0 kg, yet their resting metabolic rate was still 704 kcal a day below where it started, and 499 kcal a day lower than their body size predicted. Those who kept off the most weight showed the strongest slowing. The study is small and the weight loss was extreme, but the direction is the same one seen in larger dieting research.
The public has absorbed this more than the cheating debate suggests. In Pew Research Center's survey of 10,133 US adults, fielded from 7 to 11 February 2024, 65% said willpower alone is usually not enough for people trying to lose weight and keep it off. That is the premise the cheating argument depends on, and two-thirds of Americans already reject it. What remains is a narrower intuition: that whatever helps should still require effort from the person using it. On that point the trial designs have something specific to say, because none of the main obesity trials tested the drug on its own.
A shortcut is something you take once. Every trial of these drugs says the opposite: the effect lasts exactly as long as the treatment does.
Do people on Ozempic still have to diet and exercise?
The approved use assumes they do. The FDA label for Wegovy says it is indicated in combination with a reduced calorie diet and increased physical activity, and the Ozempic label describes the drug as an adjunct to diet and exercise in adults with type 2 diabetes. The pivotal trial, STEP 1, published in the New England Journal of Medicine in 2021, gave both arms the same lifestyle intervention. Among 1,961 adults without diabetes, average weight change at 68 weeks was 14.9% with semaglutide 2.4 mg and 2.4% with placebo. The placebo arm is the honest benchmark for effort without the drug: the same counselling, the same follow-up, and a result one sixth the size.
| Study | Who and how long | What it measured | Result |
|---|---|---|---|
| STEP 1 (NEJM, 2021) | 1,961 adults without diabetes, 68 weeks, lifestyle counselling in both arms | Average weight change | -14.9% with semaglutide 2.4 mg vs -2.4% with placebo |
| STEP 1 extension (Diabetes Obes Metab, 2022) | 327 participants followed to week 120, a year after stopping | Weight regained after withdrawal | 11.6 of 17.3 points regained; net loss 5.6% |
| STEP 4 (JAMA, 2021) | 803 adults who had lost 10.6% in a 20-week run-in | Continue vs switch to placebo, weeks 20 to 68 | -7.9% continued vs +6.9% on placebo |
| The Biggest Loser follow-up (Obesity, 2016) | 14 contestants measured 6 years later | Resting metabolic rate after weight loss | 704 kcal/day below baseline; 41.0 of 58.3 kg regained |
Sources: abstracts on PubMed, read on 18 November 2026. Different designs and populations: the rows show the same pattern, not comparable effect sizes.
The same paper records what the effort costs on the drug side. Nausea and diarrhoea were the most common adverse events with semaglutide, typically transient and mild to moderate, and 4.5% of people on semaglutide stopped because of them, against 0.8% on placebo. That is not a description of an easy way out. It is a description of a treatment with a real burden, used alongside the same diet and exercise advice everyone else gets, and producing a much larger effect. Whether that larger effect is fair is the next question, and it depends entirely on what happens when the treatment ends.
What happens when you stop taking Ozempic?
When people stop semaglutide, most of the lost weight comes back, which is the strongest evidence that the drug is a treatment rather than a shortcut. The STEP 1 extension, published in Diabetes, Obesity and Metabolism in 2022, followed 327 participants for a year after treatment and lifestyle support ended at week 68. They had lost an average of 17.3% on semaglutide. By week 120 they had regained 11.6 percentage points, leaving a net loss of 5.6%, and most of the cardiometabolic improvements seen on treatment moved back toward baseline. The authors' summary is plain: participants regained two-thirds of their prior weight loss within a year of withdrawal.
STEP 4, published in JAMA in 2021, tested the same point with randomisation. All 902 participants took semaglutide for 20 weeks, and the 803 who reached the full dose had lost 10.6% on average. They were then split: those who continued lost a further 7.9% by week 68, while those switched to placebo gained 6.9%. We cover how that trial is often misquoted in our close reading of STEP 4. A shortcut is something you take once. Both trials show an effect that lasts exactly as long as the treatment does, the same pattern seen with blood pressure or cholesterol drugs, which nobody describes as cheating.
Is it cheating to use GLP-1 drugs without obesity?
The no-condition case is the strongest version of the cheating argument, and the data support part of it. In Pew's February 2024 survey, 53% of Americans familiar with the drugs called them a good option for people with obesity or a weight-related health condition. Only 12% said the same for people who want to lose weight but have no such condition, and 62% said they were not a good option. The public is not objecting to treatment. It is objecting to cosmetic use by people outside the trial populations, where the balance of benefit against side effects, cost and the need to keep taking the drug has not been tested. The label draws a similar line: Wegovy is approved for obesity, or overweight with at least one weight-related condition.
Use is also no longer marginal, which is why the line matters. A KFF poll fielded from 27 October to 2 November 2025 among 1,350 US adults found 12% currently taking a GLP-1 drug and 18% who had ever taken one, up from about 6% current use in 2024. KFF's figures cover diabetes and other conditions as well as weight loss, so they do not measure cosmetic use directly. There is one setting where "cheating" is the right word: sport with weight classes or doping rules, where any undeclared advantage breaks a written rule. Outside that, the accurate word for off-label cosmetic use is not cheating but untested, and untested is a medical concern, not a moral one.
What should the question be instead?
The better question is not whether someone earned their weight loss but whether a treatment fits their condition, and the evidence gives a usable answer. For people with clinical obesity, as the Lancet Commission defines it, the drugs act on a body that defends its weight through genes and metabolism, and they work only while taken, alongside the same diet and exercise advice the placebo arms received. For people without a weight-related condition, the honest objection is not that they are cheating but that the trials never studied them. Keeping those two cases apart is how to follow this debate without the moral noise. Our regulatory tracker follows which drugs are approved, which are not, and what changes next, and the newsletter sends each update with its source.
Sources
- Wilding JPH et al., Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), N Engl J Med 2021;384:989-1002. pubmed.ncbi.nlm.nih.gov
- Wilding JPH et al., Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension, Diabetes Obes Metab 2022;24:1553-1564. pubmed.ncbi.nlm.nih.gov
- Rubino D et al., Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4), JAMA 2021. pubmed.ncbi.nlm.nih.gov
- Fothergill E et al., Persistent metabolic adaptation 6 years after "The Biggest Loser" competition, Obesity 2016;24:1612-1619. pubmed.ncbi.nlm.nih.gov
- Elks CE et al., Variability in the heritability of body mass index: a systematic review and meta-regression, Front Endocrinol 2012;3:29. pubmed.ncbi.nlm.nih.gov
- Rubino F et al., Definition and diagnostic criteria of clinical obesity (Lancet Commission), Lancet Diabetes Endocrinol 2025;13:221-262. pubmed.ncbi.nlm.nih.gov
- Pew Research Center, How Americans view weight-loss drugs and their potential impact on obesity in the U.S., 26 February 2024. www.pewresearch.org
- KFF, Poll: 1 in 8 adults say they are currently taking a GLP-1 drug, 14 November 2025. www.kff.org
- FDA, Wegovy prescribing information, Indications and Usage, via the openFDA label dataset, read on 18 November 2026. api.fda.gov
